Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA

Blood. 2017 Jun 8;129(23):3126-3129. doi: 10.1182/blood-2016-06-721712. Epub 2017 Apr 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Hypoxia / drug effects
  • Central Nervous System Neoplasms* / drug therapy
  • Central Nervous System Neoplasms* / metabolism
  • Central Nervous System Neoplasms* / pathology
  • Humans
  • Mice
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / metabolism
  • Vascular Endothelial Growth Factor A / pharmacology*
  • Xenograft Model Antitumor Assays

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A